一项关于依托泊苷和粒细胞集落刺激因子联合或不联合利妥昔单抗用于B细胞非霍奇金淋巴瘤外周血干细胞动员的随机试验。
A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
作者信息
Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S, Dean R, Koo A, Chan J, Sweetenham J, Bolwell B
机构信息
Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
出版信息
Bone Marrow Transplant. 2009 Jan;43(2):101-5. doi: 10.1038/bmt.2008.306. Epub 2008 Sep 15.
Some reports have suggested that rituximab administration before PBSC mobilization may adversely affect PBSC yield. We conducted a prospective randomized trial of PBSC mobilization using etoposide and G-CSF with or without rituximab to determine whether its addition would adversely affect CD34+ cell yield in patients with non-Hodgkin's lymphoma. Twenty seven patients were mobilized with etoposide and G-CSF and 28 with etoposide, G-CSF and rituximab. There were no adverse consequences of rituximab on CD34+ cell yield, or hematopoietic recovery or immunoglobulin levels after transplantation.
一些报告表明，在进行外周血干细胞（PBSC）动员之前给予利妥昔单抗可能会对PBSC产量产生不利影响。我们进行了一项前瞻性随机试验，使用依托泊苷和粒细胞集落刺激因子（G-CSF）进行PBSC动员，其中一组加用利妥昔单抗，另一组不加，以确定添加利妥昔单抗是否会对非霍奇金淋巴瘤患者的CD34+细胞产量产生不利影响。27例患者使用依托泊苷和G-CSF进行动员，28例患者使用依托泊苷、G-CSF和利妥昔单抗进行动员。利妥昔单抗对移植后的CD34+细胞产量、造血恢复或免疫球蛋白水平均无不良影响。
Zotero 插件